TheraVida, SK Chemicals in South Korea OAB Pact

TheraVida and SK Chemicals Co. have entered a license agreement for two of TheraVida’s combination drug product candidates, THVD-201 and THVD-202. SK Chemicals has exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). THVD-201 has successfully completed Phase I and Phase II development and THVD-202 is completing preclinical development.
 
SK Chemicals is responsible for costs associated with manufacturing, further clinical development, regulatory approval, and commercialization of THVD-201 and THVD-202 in the territory. TheraVida will receive milestone payments and royalties on sales. Financial terms were not disclosed.
 
“TheraVida is enthusiastic about working in partnership with SK Chemicals, one of the leading pharmaceutical companies in South Korea, on the development and commercialization of THVD-201 and THVD-202,” said Roger Flugel, Ph.D., chief executive officer of TheraVida. “THVD-201 and THVD-202 have the potential to offer significant improvement in dry mouth side effects and better efficacy over current standard-of-care therapies for OAB and UUI. We believe these products can ultimately increase the overall tolerability, compliance, and satisfaction for patients suffering from these conditions.”